Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Gynecologic Cancers
•
Ovarian Cancer
When prescribing bevacizumab for high-risk primary ovarian cancer, do you use 15mg/m2 q 21 days (per GOG 218) or 7.5mg/m2 q 21 days (per ICON7)?
Related Questions
Would you recommend SBRT in the adjuvant settings for a solitary metastasis focus in the abdominal wall resected to R1 in a young and healthy patient with clear cell ovarian cancer?
Do you test ovarian cancer tumors for targetable biomarkers (e.g., HER2, folate receptor, MMR) at the time of primary diagnosis or at time of recurrence?
Do you recommend bevacizumab with front-line platinum-based adjuvant chemotherapy for fully resected stage III ovarian clear cell carcinoma?
How would you manage a patient with an incidental finding of 1 mm focus of high-grade serous carcinoma in the fallopian tube after TAHBSO was done for a benign broad ligament fibroid with negative pelvic washings?
Would you recommend surgery or stereotactic radiation therapy for a young woman with high-grade serous ovarian cancer presenting with a pelvic LN oligometastasis following maintenance therapy?
What platform do you use for HRD testing of ovarian cancers and why?
What second-line therapy would you recommend for a patient with a pathogenic BRCA-1 mutation and stage IIIA fallopian tube high-grade serous carcinoma, who underwent R0 cytoreduction followed by 6 cycles of carboplatin/paclitaxel with complete response, who has now progressed 13 months into olaparib maintenance?
In a patient with an HR-proficient stage III high-grade serous ovarian cancer s/p R0 primary debulking surgery for whom you are not considering bevacizumab in addition to chemotherapy, would you consider IP chemotherapy?
How do you incorporate a KELIM score into your management of patients with ovarian cancer?
Would you ever re-treat recurrent ovarian cancer with mirvetuximab soravtansine if the patient responded to it in the past (e.g., more than 6 months ago)?
